Combination of Continuous Femoral Block and Intravenous Parecoxib For Postoperative Analgesia After Total Knee Arthroplasty

Asklepieion Voulas General Hospital

Status and phase: Completed; Phase 3; Phase 2

Conditions: POSTOPERATIVE ANALGESIA FOR TKA PARECOXIB/CFB

Treatments: Drug: N/S 0.9%; Drug: Parecoxib; Drug: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%

Study type: Interventional

Funder types: Other

Identifiers

NCT02185924

S-138/15-06-10

Details and patient eligibility

About

Combination of continuous femoral block with parEcoxib vs placebo. Investigation of morphine consumption, opioid sparing effects, VAS pain scores, haemodynamics, Anxierty scores, transfusion requirements , Range of motion and rehabilitation parameters between two groups

Enrollment: 90 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• PATIENTS ASA I-II UNDERGOING TOTAL KNEE ATRTHROPLASTY

Exclusion criteria

Exclusion criteria for both groups included:

• Age younger than 40 years old or older than 80 years old
• ASA > III
• Obesity (>140 kg body weight)
• Allergy to local anesthetics
• History dependence on opioids
• Contraindications for subarachnoid anesthesia or femoral block (coagulopathy, local infection, pre-existing neurological problems, patient refusal)
• Contraindications to the administration of parecoxib
• Severe hepatic or renal disease (serum creatinine ≥ 1.7 mg/dl)

Trial design

90 participants in 2 patient groups, including a placebo group

CONTINUOUS FEMORAL BLOCK AND PARECOXIB

Experimental group

Description:

Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib

Treatment:

Drug: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%

Drug: Parecoxib

CONTINUOUS FEMORAL BLOCK AND PLACEBO

Placebo Comparator group

Description:

Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%

Treatment:

Drug: CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%

Drug: N/S 0.9%